➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Merck
Dow
Harvard Business School
AstraZeneca

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Litigation Details for Cephalon, Inc. v. Slayback Pharma Limited Liability Company (D. Del. 2017)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Cephalon, Inc. v. Slayback Pharma Limited Liability Company (D. Del. 2017)

Docket   Start Trial Date Filed 2017-08-16
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Colm Felix Connolly
Jury Demand None Referred To
Parties APOTEX CORP.; APOTEX INC.; CEPHALON, INC.; EAGLE PHARMACEUTICALS, INC.; FRESENIUS KABI USA, LLC; MYLAN LABORATORIES LIMITED; SLAYBACK PHARMA LIMITED LIABILITY COMPANY; TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Patents 10,112,981; 10,188,728; 10,188,730; 10,188,745; 10,189,797; 10,215,746; 10,247,737; 10,280,430; 10,307,579; 10,334,848; 10,364,437; 10,369,409; 10,370,679; 10,375,981; 10,376,505; 10,376,564; 10,376,568; 10,376,579; 10,376,583; 10,376,601; 10,376,652; 10,376,658; 10,383,875; 10,383,918; 10,383,920; 10,383,923; 10,398,669; 10,398,730; 10,406,160; 10,406,332; 10,406,383; 10,407,434; 10,407,488; 10,413,505; 10,413,543; 10,413,564; 10,413,568; 10,413,569; 10,413,593; 10,420,723; 10,420,816; 10,420,838; 10,420,841; 10,488,413; 10,488,416; 10,519,226; 10,568,841; 10,568,908; 10,568,934; 10,597,432; 10,597,433; 10,597,434; 10,597,728; 10,624,875; 6,190,659; 6,268,399; 6,280,993; 6,340,695; 6,403,569; 6,405,764; 6,406,731; 6,416,999; 6,425,676; 6,436,713; 6,505,597; 6,562,793; 6,569,430; 6,579,968; 6,579,981; 6,623,959; 6,629,968; 6,652,394; 6,652,398; 6,652,921; 6,676,746; 6,682,904; 6,695,722; 6,695,723; 6,723,340; 6,726,918; 6,736,695; 6,740,669; 6,746,681; 6,747,189; 6,755,420; 6,764,419; 6,764,678; 6,793,959; 6,875,904; 6,899,648; 6,908,591; 6,923,737; 6,923,968; 6,923,984; 6,979,437; 6,979,829; 6,984,403; 6,987,103; 6,988,968; 6,991,394; 7,189,740; 7,223,554; 7,226,629; 7,226,793; 7,280,816; 7,320,968; 7,320,997; 7,323,623; 7,334,488; 7,334,695; 7,361,676; 7,364,736; 7,364,740; 7,371,408; 7,371,409; 7,374,747; 7,378,488; 7,410,664; 7,410,797; 7,427,602; 7,428,875; 7,432,265; 7,435,427; 7,435,755; 7,468,372; 7,473,543; 7,569,554; 7,572,448; 7,579,189; 7,579,473; 7,591,745; 7,597,901; 7,601,740; 7,601,746; 7,601,758; 7,654,921; 7,654,997; 7,658,918; 7,659,282; 7,678,399; 7,682,624; 7,713,737; 7,713,999; 7,718,425; 7,722,898; 7,728,190; 7,728,191; 7,731,648; 7,737,112; 7,745,409; 7,758,889; 7,816,323; 7,816,379; 7,816,383; 7,829,120; 7,829,320; 7,829,659; 7,838,504; 7,838,505; 7,838,564; 7,841,372; 7,847,486; 7,875,435; 7,875,664; 7,875,726; 7,879,334; 7,879,816; 7,887,844; 7,901,687; 7,915,247; 7,915,307; 7,923,432; 7,923,564; 7,942,764; 7,959,920; 7,959,942; 7,959,999; 7,968,569; 7,981,088; 7,981,416; 7,981,418; 7,981,889; 7,982,075; 7,982,077; 7,982,078; 7,985,408; 7,985,418; 7,985,745; 7,993,219; 7,993,222; 7,993,223; 7,993,629; 8,088,737; 8,088,934; 8,112,934; 8,112,942; 8,152,658; 8,188,844; 8,222,484; 8,226,505; 8,247,425; 8,268,847; 8,323,942; 8,361,959; 8,372,431; 8,372,432; 8,372,434; 8,372,624; 8,372,968; 8,376,993; 8,379,486; 8,383,655; 8,383,887; 8,398,993; 8,403,923; 8,409,579; 8,409,616; 8,419,722; 8,420,629; 8,420,674; 8,420,676; 8,425,934; 8,431,597; 8,435,505; 8,435,554; 8,435,942; 8,486,898; 8,486,981; 8,486,991; 8,486,993; 8,546,372; 8,546,409; 8,562,979; 8,562,981; 8,562,982; 8,568,713; 8,568,740; 8,568,747; 8,568,793; 8,568,979; 8,583,380; 8,591,899; 8,597,654; 8,597,655; 8,597,681; 8,597,713; 8,602,920; 8,616,723; 8,623,418; 8,623,591; 8,623,901; 8,623,920; 8,652,484; 8,658,676; 8,664,215; 8,669,245; 8,679,473; 8,679,569; 8,679,844; 8,695,189; 8,722,410; 8,722,679; 8,728,332; 8,728,519; 8,728,546; 8,728,730; 8,740,982; 8,747,847; 8,747,904; 8,753,679; 8,758,726; 8,758,816; 8,791,270; 8,829,175; 8,841,087; 8,841,125; 8,887,981; 8,889,190; 8,889,191; 8,889,600; 8,889,616; 8,889,722; 8,889,740; 8,889,831; 8,901,374; 8,901,378; 8,901,484; 8,915,889; 8,920,383; 8,921,374; 8,952,043; 8,968,724; 8,968,726; 8,968,753; 8,979,682; 8,981,064; 8,981,103; 8,987,421; 8,987,487; 8,987,554; 8,991,403; 8,993,250; 8,993,519; 8,993,624; 8,993,838; 8,999,340; 8,999,398; 8,999,728; 8,999,915; 9,066,942; 9,089,756; 9,092,952; 9,125,816; 9,125,889; 9,144,568; 9,226,934; 9,265,723; 9,265,737; 9,265,740; 9,265,758; 9,265,831; 9,265,887; 9,271,968; 9,282,745; 9,340,797; 9,364,436; 9,364,437; 9,370,629; 9,375,434; 9,376,505; 9,383,370; 9,403,904; 9,404,915; 9,408,746; 9,408,904; 9,408,979; 9,408,993; 9,409,987; 9,409,997; 9,416,371; 9,422,593; 9,433,219; 9,433,371; 9,433,624; 9,434,915; 9,434,997; 9,468,676; 9,468,682; 9,468,747; 9,468,829; 9,486,406; 9,486,408; 9,486,682; 9,488,654; 9,504,655; 9,504,669; 9,505,722; 9,505,841; 9,546,369; 9,546,372; 9,554,968; 9,562,904; 9,572,484; 9,572,797; 9,572,856; 9,572,887; 9,579,421; 9,593,374; 9,593,378; 9,597,374; 9,597,399; 9,597,409; 9,597,591; 9,597,659; 9,624,152; 9,624,307; 9,629,797; 9,629,831; 9,629,841; 9,629,847; 9,629,899; 9,629,920; 9,629,959; 9,655,979; 9,687,474; 9,687,581; 9,695,422; 9,695,428; 9,695,437; 9,713,543; 9,713,629; 9,718,841; 9,723,844; 9,724,323; 9,724,378; 9,724,380; 9,724,391; 9,724,394; 9,724,405; 9,724,410; 9,724,415; 9,726,669; 9,730,915; 9,730,934; 9,730,993; 9,737,399; 9,737,488; 9,737,554; 9,737,572; 9,737,591; 9,737,669; 9,745,334; 9,750,713; 9,750,726; 9,750,747; 9,750,793; 9,756,687; 9,758,829; 9,793,659; 9,797,901; 9,829,487; 9,841,424; 9,844,505; 9,844,581; 9,844,601; 9,844,655; 9,856,265; 9,856,320; 9,856,323; 9,889,144; 9,901,623; 9,901,629; 9,901,724; 9,915,659; 9,918,468; 9,918,654; 9,921,222; 9,952,219; 9,968,655; 9,968,658; 9,968,659; 9,968,674; 9,968,676; 9,981,041; 9,981,058; 9,981,087; 9,982,051; 9,987,271; 9,987,332; 9,987,334; 9,987,369; 9,987,416; 9,988,406; 9,988,422; 9,988,432; 9,988,437; 9,993,474; 9,993,554; 9,993,568; 9,999,593; 9,999,655
Attorneys Adam D. Harber; Alex M. Grabowski; Anjali D. Deshmukh; Anna G. Phillips; Arun John Mohan; Ben V. Picozzi; Beth C. Finkelstein; Bobby Delafield; Brian E. Farnan; Constance S. Huttner; Damien Nicholas Tancredi; Daniel G. Brown; David A. Bilson; David I. Berl; David S. Steuer; Elise M. Baumgarten; Eve H. Ormerod; Frank D. Rodriguez; Helen H. Ji; Imron T. Aly; James Michael Lennon; James P. Barabas; Jeffrey A. Cohen; Jeremy S. Cole; John C. Phillips , Jr.; John D. Cravero; John W. Shaw; Karen Elizabeth Keller; Kenneth G. Schuler; Kevin M. Nelson; Marc N. Zubick; Martha C. Kidd; Matthew Lachman; Megan C. Haney; Michael J. Farnan; Michelle L. Ernst; Nathan Roger Hoeschen; Neal C. Belgam; Nicole W. Stafford; Rhyea Malik; Shaun P. Mahaffy; Sherry L. Rollo; Shyamkrishna Palaiyanur; Steven E. Feldman
Firms Devlin Law Firm LLC; Farnan LLP; Flaster Greenburg, P.C.; Phillips, Goldman, McLaughlin & Hall, P.A.; Schiff Hardin LLP; Shaw Keller LLP; Smith, Katzenstein, & Jenkins LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Cephalon, Inc. v. Slayback Pharma Limited Liability Company
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Cephalon, Inc. v. Slayback Pharma Limited Liability Company

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Cephalon, Inc. v. Slayback Pharma Limited Liability Company (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
2020-04-27 394 Opinion Treanda®. Tr. 981:25−82:2, 1657:10−11. In 2015, Teva acquired Cephalon, Tr. 1660:10−14, and Cephalon…enablement under 35 U.S.C. § 112; and (4) claim 9 of the #797 patent is invalid for lack of written … and without the antioxidant, #831 patent at 12 Section 112(b) of Title 35 provides that “[t]he…#568 patent, and (2) July 10, 2012 for the remaining administration claims. D.I. 332; Tr. 2015:10-16.… at any temperature. Tr. 1485:4−87:10, 1502:8−12. And the patents provide a POSITA with a method for External link to document
2020-07-06 406 Order - -Memorandum and Order all the patents that were asserted in the case by Plaintiffs except for U.S. Patent No. 8,791,270. The …respectively, with the exception of U.S. Patent No. 8,791,270, which has been resolved by the granting… 8,791,270, which has been resolved by the granting of a consent judgment." D.I. 319 ,r 4. …of the patent that has been asserted by Slayback in this case, with the exception of U.S. Patent No. 8,791,270…either infringe the asserted patents or don't infringe the asserted patents. I note in this regard that External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
McKinsey
Colorcon
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.